A type of cancer treatment known as CAR T therapy has shown great promise for blood cancer treatments in the last decade, but too often, patients relapse within a short time. Now, a team of researchers has uncovered some critical clues about why – potentially leading to treatments to prevent these relapses.
J. Joseph Melenhorst, PhD, has been appointed director of Cleveland Clinic’s new cell therapy and immuno-engineering program.Melenhorst also will serve as vice chair of Center for Immunotherapy and Precision Immuno-Oncology.
Long-term chimeric antigen receptor (CAR) T cell signaling and persistence has been demonstrated at more than 10 years after infusion in two chronic lymphocytic leukemia (CLL) patients.
TUESDAY, Feb. 15, 2022 (HealthDay News) Long-term chimeric antigen receptor (CAR) T cell signaling and persistence has been demonstrated at more than 10.